Anti-IFN therapies, including sifalimumab (an anti-IFN-α monoclonal antibody) and anifrolumab (a monoclonal antibody targeting the IFN-I receptor), have demonstrated favorable outcomes in phase II randomized controlled trials involving adult SLE patients with moderate-to-severe disease [118–120]. Here, IFNA1 is linked to systemic lupus erythematosus.